AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19631122 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal hydration with balanced salt solution
Number of subjects: 30
Study 19631122 — intervention group
Group type: COMPARATOR
Intervention: No stromal hydration
Number of subjects: 30
Study 19631122 — intervention group
Group type: EXPERIMENTAL
Intervention: Stromal hydration
Number of subjects: 30
Study 16339833 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized hyperventilation
Number of subjects: 16
Study 16339833 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized handgrip
Number of subjects: 16
Study 15552725 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-weighted spin-echo imaging (T1-SE)
Number of subjects: 48
Study 15552725 — intervention group
Group type: EXPERIMENTAL
Intervention: T1-weighted opposed-phase gradient-echo imaging (T1-opposed GRE)
Number of subjects: 48
Study 15552725 — intervention group
Group type: COMPARATOR
Intervention: Comparison between T1-SE and T1-opposed GRE
Number of subjects: 48
Study 10982755 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg risedronate (n = 255)
Number of subjects: 515
Study 10982755 — intervention group
Group type: COMPARATOR
Intervention: 10 mg alendronate (n = 260)
Number of subjects: 515
Study 10982755 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg risedronate
Number of subjects: 515
Study 10982755 — intervention group
Group type: COMPARATOR
Intervention: 10 mg alendronate
Number of subjects: 515
Study 8981708 — intervention group
Group type: EXPERIMENTAL
Intervention: Alredase (intervention)
Number of subjects: 3679
Study 8981708 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 3679
Study 1282602 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (62.5 micrograms/kg)
Number of subjects: 10
Study 1282602 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (62.5 micrograms/kg)
Number of subjects: 10
Study 1282602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (7.5 micrograms/kg)
Number of subjects: 10
Study 1282602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1282602 — intervention group
Group type: COMPARATOR
Intervention: Combined EPI and atropine (15 micrograms/kg) after placebo
Number of subjects: 10
Study 1282602 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI and atropine
Number of subjects: 10
Study 6325065 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg daily
Number of subjects: 35
Study 6325065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31075150 — intervention group
Group type: EXPERIMENTAL
Intervention: Standards-Based Management and Recognition (SBM-R) approach in intervention zones
Number of subjects: 426
Study 31075150 — intervention group
Group type: COMPARATOR
Intervention: Comparison zones
Number of subjects: 426
Study 30066362 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaire every 4 days)
Number of subjects: 45
Study 30066362 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring group (questionnaire + 'say no' to indulgences)
Number of subjects: 45
Study 30066362 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring and feedback group (questionnaire + 'say no' + feedback)
Number of subjects: 45
Study 27799644 — intervention group
Group type: EXPERIMENTAL
Intervention: CHoBI7 intervention (handwashing with soap and water treatment during hospital stay and home visits)
Number of subjects: 604
Study 27799644 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 604
Study 25239292 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained by schoolteachers in basic first aid
Number of subjects: 285
Study 25239292 — intervention group
Group type: COMPARATOR
Intervention: Untrained (control group)
Number of subjects: 285
Study 22790403 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (60 mg/day)
Number of subjects: 30
Study 22790403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19932167 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous carriers of the AluYb8MYH mutation
Number of subjects: 1708
Study 17380213 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate and atorvastatin calcium single-pill combination (5 or 10 mg amlodipine and 10 mg atorvastatin)
Number of subjects: 0
Study 17380213 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate and atorvastatin calcium single-pill combination
Number of subjects: 0
Study 15674307 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA supplementation (3g/day; 50:50 mix of the two major isomers)
Number of subjects: 28
Study 15674307 — intervention group
Group type: COMPARATOR
Intervention: High oleic sunflower oil (reference)
Number of subjects: 28
Study 14622675 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy intervention
Number of subjects: 45
Study 14622675 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory information intervention
Number of subjects: 45
Study 14622675 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 45
Study 10233185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg b.d. orally
Number of subjects: 12
Study 10233185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8966140 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 25% magnesium sulphate infusion (20 ml dissolved in 500 ml 5% dextrose for 60 minutes)
Number of subjects: 43
Study 8966140 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 43
Study 1919373 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraspinal skin temperature differential instrument
Number of subjects: 19
Study 1919373 — intervention group
Group type: EXPERIMENTAL
Intervention: First observation between examiners
Number of subjects: 19
Study 1919373 — intervention group
Group type: EXPERIMENTAL
Intervention: Second observation between examiners
Number of subjects: 19
Study 1919373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraexaminer agreement for one examiner
Number of subjects: 19
Study 1919373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraexaminer agreement for the other examiner
Number of subjects: 19
Study 6556391 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary prevention
Number of subjects: 56
Study 6556391 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study 29989964 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 3D Label Stereo Matching using local expansion moves
Number of subjects: 0
Study 29989964 — intervention group
Group type: COMPARATOR
Intervention: Traditional expansion moves
Number of subjects: 0
Study 29989964 — intervention group
Group type: COMPARATOR
Intervention: Fusion moves or belief propagation
Number of subjects: 0
Study 28599949 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine-ER (600 mg/day)
Number of subjects: 113
Study 28599949 — intervention group
Group type: COMPARATOR
Intervention: Aripiprazole (20 mg/day)
Number of subjects: 113
Study 26138780 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 16
Study 23561069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness‐Based Stress Reduction group
Number of subjects: 10
Study 20632462 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estradiol therapy (ET)
Number of subjects: 216
Study 20632462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 18198413 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 min occlusion during high estrogenic phase
Number of subjects: 120
Study 18198413 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 min occlusion
Number of subjects: 120
Study 18198413 — intervention group
Group type: COMPARATOR
Intervention: 1, 2, or 3 min occlusion
Number of subjects: 120
Study 16338502 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and case management for 6 months (treatment group)
Number of subjects: 188
Study 16338502 — intervention group
Group type: COMPARATOR
Intervention: Written list of services (control group)
Number of subjects: 188
Study 15505445 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane‐remifentanil (</= 0.1 microg . kg . min)
Number of subjects: 40
Study 15505445 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane‐remifentanil (>/= 0.2 microg . kg . min)
Number of subjects: 40
Study 15505445 — intervention group
Group type: COMPARATOR
Intervention: propofol‐remifentanil (</= 0.1 microg . kg . min)
Number of subjects: 40
Study 15505445 — intervention group
Group type: COMPARATOR
Intervention: propofol‐remifentanil (>/= 0.2 microg . kg . min)
Number of subjects: 40
Study 10706965 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A/B vaccine
Number of subjects: 282
Study 10706965 — intervention group
Group type: COMPARATOR
Intervention: Monovalent hepatitis B vaccine
Number of subjects: 282
Study 9085952 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 IU of oxytocin
Number of subjects: 40
Study 9085952 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 IU of oxytocin
Number of subjects: 40
Study 9085952 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 IU of oxytocin
Number of subjects: 40
Study 9085952 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 IU of oxytocin
Number of subjects: 40
Study 9085952 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (5, 10, 15, 20 IU of oxytocin)
Number of subjects: 40
Study 8227917 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking group (exercised at 60% heart rate reserve for 30 to 40 minutes, 5 days a week for 12 weeks)
Number of subjects: 32
Study 8227917 — intervention group
Group type: EXPERIMENTAL
Intervention: Calisthenic group (engaged in mild range-of-motion and flexibility movements for 30 to 40 minutes, 5 days a week for 12 weeks)
Number of subjects: 32
Study 8227917 — intervention group
Group type: COMPARATOR
Intervention: Highly conditioned elderly women (cross-sectional comparison)
Number of subjects: 32
Study 8227917 — intervention group
Group type: COMPARATOR
Intervention: Sedentary elderly women (baseline comparison)
Number of subjects: 32
Study 3754834 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (800 mg daily, 200 mg intravenously 4 times a day for 7 days)
Number of subjects: 89
Study 3754834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 2450026 — intervention group
Group type: EXPERIMENTAL
Intervention: sotalol 160 mg b.d.
Number of subjects: 103
Study 2450026 — intervention group
Group type: COMPARATOR
Intervention: atenolol 50 mg b.d.
Number of subjects: 103
Study 31033008 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative Extracorporeal Shockwave Therapy (ESWT)
Number of subjects: 24
Study 31033008 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 29909374 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Command Hallucinations (CTCH)
Number of subjects: 98
Study 27688717 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthyActions intervention group
Number of subjects: 1052
Study 24346114 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamphetamine (0.45 mg/kg, per os)
Number of subjects: 64
Study 24346114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 23443332 — intervention group
Group type: COMPARATOR
Intervention: Resistance training with placebo
Number of subjects: 0
Study 23443332 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with glucosamine
Number of subjects: 0
Study 23443332 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training with NSAID
Number of subjects: 0
Study 23443332 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training overall
Number of subjects: 0
Study 21157050 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mouth rinse
Number of subjects: 45
Study 21157050 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse
Number of subjects: 45
Study 18815960 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship-facilitating interventions (empathy, positive regard)
Number of subjects: 0
Study 18815960 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment-oriented interventions (relational reframes, addressing core relational themes, highlighting vulnerable emotions)
Number of subjects: 0
Study 18815960 — intervention group
Group type: COMPARATOR
Intervention: Comparison interventions
Number of subjects: 0
Study 16802248 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EG)
Number of subjects: 40
Study 16802248 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined EMS and Plyometric training (EPG)
Number of subjects: 40
Study 15318495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic drip filters
Number of subjects: 0
Study 15318495 — intervention group
Group type: COMPARATOR
Intervention: Customary sources of drinking water (Control)
Number of subjects: 0
Study 10940548 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin
Number of subjects: 10
Study 10940548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9078541 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (0.2 g.kg‐1.d‐1 on the day of the study) supplemented formula
Number of subjects: 11
Study 9078541 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric, enteral preterm formula alone
Number of subjects: 11
Study 8104348 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg haloperidol i.v. for 3 days followed by 3 x 5 mg haloperidol p.o./d
Number of subjects: 50
Study 8104348 — intervention group
Group type: COMPARATOR
Intervention: 3 x 100 mg perazin p.o./d
Number of subjects: 50
Study 3743144 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fenoterol
Number of subjects: 12
Study 3743144 — intervention group
Group type: COMPARATOR
Intervention: Placebo bronchodilator
Number of subjects: 12
Study 3743144 — intervention group
Group type: COMPARATOR
Intervention: Inhaled fenoterol and placebo
Number of subjects: 12
Study 30419088 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (SRS)
Number of subjects: 268
Study 30419088 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 268
Study 30172363 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter Aortic Valve Implantation (TAVI)
Number of subjects: 739
Study 30172363 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Aortic Valve Replacement (SAVR)
Number of subjects: 739
Study 26125285 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of soy isoflavones (60 mg) administered concomitantly with levothyroxine
Number of subjects: 12
Study 26125285 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine administered 6 hours after soy isoflavones
Number of subjects: 12
Study 25348002 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-PEG2500
Number of subjects: 165
Study 25348002 — intervention group
Group type: EXPERIMENTAL
Intervention: SC-PEG
Number of subjects: 165
Study 25348002 — intervention group
Group type: COMPARATOR
Intervention: SS-PEG2500
Number of subjects: 165
Study 23147689 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers (BB) therapy for 12 weeks
Number of subjects: 30
Study 18575771 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sucralfate (SUC‐LIS 95) applied daily for a median period of 42.0 days
Number of subjects: 50
Study 18575771 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 50
Study 18575771 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sucralfate (SUC‐LIS 95)
Number of subjects: 50
Study 16019690 — intervention group
Group type: EXPERIMENTAL
Intervention: High vitamin C levels
Number of subjects: 1020
Study 16019690 — intervention group
Group type: EXPERIMENTAL
Intervention: High vitamin E levels
Number of subjects: 1020
Study 12446075 — intervention group
Group type: EXPERIMENTAL
Intervention: FilterWire EX distal protection system
Number of subjects: 278
Study 11409190 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine drops
Number of subjects: 0
Study 11409190 — intervention group
Group type: COMPARATOR
Intervention: Marketed fluoxetine capsules
Number of subjects: 0
Study 9107582 — intervention group
Group type: EXPERIMENTAL
Intervention: LT02 SWL
Number of subjects: 1363
Study 9107582 — intervention group
Group type: COMPARATOR
Intervention: LT01 SWL
Number of subjects: 1363
Study 8210919 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac SR 400 mg once daily (q.d.)
Number of subjects: 404
Study 8210919 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac SR 600 mg once daily (q.d.)
Number of subjects: 404
Study 8210919 — intervention group
Group type: COMPARATOR
Intervention: etodolac 200 mg twice daily (b.i.d.)
Number of subjects: 404
Study 8210919 — intervention group
Group type: COMPARATOR
Intervention: etodolac 300 mg twice daily (b.i.d.)
Number of subjects: 404
Study 8210919 — intervention group
Group type: EXPERIMENTAL
Intervention: etodolac SR
Number of subjects: 404
Study 8210919 — intervention group
Group type: COMPARATOR
Intervention: conventional etodolac
Number of subjects: 404
Study 3513715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 2 mg/kg/day in two divided doses for five days
Number of subjects: 38
Study 3513715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 3513715 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 38
Study 31272216 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density suture spacing (approximately 5 mm apart)
Number of subjects: 0
Study 31272216 — intervention group
Group type: COMPARATOR
Intervention: Low-density suture spacing (approximately 10 mm apart)
Number of subjects: 0
Study 28301043 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Treatment Optimization Programme (TTOP)
Number of subjects: 1790
Study 28301043 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (non-TTOP)
Number of subjects: 1790
Study 26214440 — intervention group
Group type: EXPERIMENTAL
Intervention: RFT at 70°C with PRF (42°C, 2 Hz, 240 s)
Number of subjects: 80
Study 26214440 — intervention group
Group type: EXPERIMENTAL
Intervention: RFT at 75°C with PRF (42°C, 2 Hz, 240 s)
Number of subjects: 80
Study 26214440 — intervention group
Group type: COMPARATOR
Intervention: RFT at 75°C without PRF
Number of subjects: 80
Study 26214440 — intervention group
Group type: COMPARATOR
Intervention: RFT at 70°C without PRF
Number of subjects: 80
Study 26214440 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined RFT and PRF
Number of subjects: 80
Study 23784346 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) 500 mg oral single dose
Number of subjects: 14
Study 21690118 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based behavioral weight loss treatment (FBT)
Number of subjects: 204
Study 19559476 — intervention group
Group type: COMPARATOR
Intervention: Eflornithine (400 mg/kg per day, every 6 h) for 14 days
Number of subjects: 287
Study 19559476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox-eflornithine combination therapy (NECT): Eflornithine (400 mg/kg per day, every 12 h) for 7 days with oral Nifurtimox (15 mg/kg per day, every 8 h) for 10 days
Number of subjects: 287
Study 19559476 — intervention group
Group type: COMPARATOR
Intervention: Eflornithine
Number of subjects: 287
Study 19559476 — intervention group
Group type: EXPERIMENTAL
Intervention: NECT
Number of subjects: 287
Study 16750298 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic back pain patients
Number of subjects: 18
Study 16750298 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 18
Study 15129707 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated SPET
Number of subjects: 78
Study 11063062 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief 7-item questionnaire screener
Number of subjects: 178
Study 11063062 — intervention group
Group type: COMPARATOR
Intervention: In-depth computerized assessment administered by an interviewer
Number of subjects: 178
Study 11063062 — intervention group
Group type: COMPARATOR
Intervention: Self-administered audio-computer assisted interview
Number of subjects: 178
Study 9284898 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (0.5 g/min in the last 60 minutes of the clamp)
Number of subjects: 12
Study 9284898 — intervention group
Group type: EXPERIMENTAL
Intervention: D-arginine (0.5 g/min in the last 60 minutes of the clamp)
Number of subjects: 12
Study 9284898 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% NaCl
Number of subjects: 12
Study 7951278 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic 1 at two dosage levels
Number of subjects: 0
Study 7951278 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesic 2 at two dosage levels
Number of subjects: 0
Study 7951278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3300436 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized bitolterol solution, 2.5 mg three times a day for 1 month
Number of subjects: 130
Study 3300436 — intervention group
Group type: COMPARATOR
Intervention: Nebulized isoproterenol solution, 2.5 mg three times a day for 1 month
Number of subjects: 130
Study 30273922 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps strengthening program (3 times weekly)
Number of subjects: 30
Study 30273922 — intervention group
Group type: COMPARATOR
Intervention: No attention control group
Number of subjects: 30
Study 28536027 — intervention group
Group type: EXPERIMENTAL
Intervention: BRV-TV
Number of subjects: 1182
Study 28536027 — intervention group
Group type: COMPARATOR
Intervention: RV5
Number of subjects: 1182
Study 28536027 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1182
Study 25677679 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 110/50 µg once daily
Number of subjects: 934
Study 25677679 — intervention group
Group type: COMPARATOR
Intervention: TIO 18 µg once daily + FOR 12 µg twice daily
Number of subjects: 934
Study 23305631 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg plus DMARDs
Number of subjects: 62
Study 23305631 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus DMARDs
Number of subjects: 62
Study 22124039 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive alternating current stimulation (ACS)
Number of subjects: 22
Study 22124039 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 22